Gilead Sciences Stock Tests Investor Patience as HIV Strength Offsets Oncology Setbacks
|
Gilead Sciences shares are stuck in a trading range as HIV
cash flows, a rich dividend and pipeline doubts pull in opposite directions. |
40 Million People Affected as HIV Cure Research Takes Big Step Forward
More than 40.8 million people worldwide were living with HIV in 2024, and 1.3 million were newly infected that year, according to the latest ... View article...